ストックスクリーナーアプリを入手
5.91
3.90%
-0.24
プレマーケット:
5.72
-0.19
-3.21%
Immunitybio Inc (IBRX) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say - statnews.com
A High-Stakes Surge for ImmunityBio Shares - AD HOC NEWS
Positive Regulatory Developments and Stellar Growth for ImmunityBio - AD HOC NEWS
ImmunityBio Surges on Trial Success and Saudi FDA Approvals - timothysykes.com
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth - StocksToTrade
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run - Finviz
ImmunityBio Shares Pull Back Following Significant Advance - AD HOC NEWS
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Morningstar
How Is The Market Feeling About ImmunityBio Inc? - Benzinga
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
Is It Too Late To Reassess ImmunityBio (IBRX) After The Recent Oncology Headlines? - Yahoo Finance
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - AOL.com
ImmunityBio, Inc. (IBRX) Stock Analysis: Potential Upside Of 90% For This Biotech Innovator - DirectorsTalk Interviews
ImmunityBio Stock Surge Backed by Strong Fundamentals - AD HOC NEWS
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story - simplywall.st
Clinical Data Fuels Investor Enthusiasm for ImmunityBio - AD HOC NEWS
FDA Requests More Data, IBRX Shares Fall - timothysykes.com
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
FDA Inquiry Pushes ImmunityBio Shares Down in Pre-Market - StocksToTrade
ImmunityBio rally causes $492M paper losses for short sellers - MSN
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next - TechStock²
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research - Stocktwits
HC Wainwright Issues Positive Forecast for ImmunityBio (NASDAQ:IBRX) Stock Price - MarketBeat
Short Sellers Face Mounting Pressure as ImmunityBio Shares Rebound - AD HOC NEWS
H.C. Wainwright raises Immunitybio stock price target to $10 on ANKTIVA progress - Investing.com UK
H.C. Wainwright raises Immunitybio stock price target to $10 on ANKTIVA progress By Investing.com - Investing.com South Africa
ImmunityBio amends $505 million convertible note to allow partial conversions - Investing.com
Aug PostEarnings: Is ImmunityBio Inc stock a smart retirement pickJuly 2025 Intraday Action & Safe Entry Trade Reports - baoquankhu1.vn
ImmunityBio Amends Major Insider Convertible Note Agreement - TipRanks
ImmunityBio Signs Convertible Note Amendment With Nant Capital - TradingView
Why ImmunityBio Shares Are Sinking Despite Analyst Buzz - TipRanks
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy - BioSpace
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday - TechStock²
ImmunityBio Stock Surges on Strong Commercial Momentum and Regulatory Wins - AD HOC NEWS
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year - AOL.com
Why ImmunityBio (IBRX) Is Up 16.8% After New ANKTIVA Data, FDA Progress And Saudi Approvals - simplywall.st
USA–Saudi Biotech Alliance Summit Marks a New Era in Healthspan, Immunotherapy, and Global Scientific Partnership - ImmunityBio
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week - TechStock²
IBRX stock sees volatile session – ImmunityBio’s update in phase 2 glioblastoma trial sparks buzz - MSN
ImmunityBio Shares Tumble Following Mixed Trial Data - AD HOC NEWS
Why ImmunityBio Stock Is Skyrocketing Again Today - AOL.com
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is It Too Late To Consider ImmunityBio (IBRX) After Its Recent Share Price Surge? - Sahm
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month - Yahoo Finance
ImmunityBio, Inc. (IBRX) stock: slides as shares drop 4.91% despite promising GBM trial results - parameter.io
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study - Clinical Trials Arena
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz - Stocktwits
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update - TechStock²
0.89%
0.10%
大文字化:
|
ボリューム (24 時間):